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ABSTRACT
Background: The inhalation of Salsola kali pollen is an important cause of pollinosis during summer and early
fall throughout desert and semi-desert areas. Sal k 1 has been previously reported as a major allergen of S. kali
pollen. In this study, we produced the recombinant Sal k 1 and also its low IgE-binding mutant form. We further
compared the IgE binding ability of these two recombinant molecules.
Methods: The recombinant Sal k 1 and its low IgE-binding variant, obtained by three amino acid exchanges
(R142→S, P143→A, D144→V), were cloned and expressed in E. coli, as proteins fused with thioredoxin and His-
tags, and then purified by Ni2+ affinity chromatography. The IgE-binding capacity of the wild-type and mutated
rSal k 1 was compared using immunoblotting, ELISA and inhibition assays by ten sera from S. kali allergic pa-
tients. Moreover, in vivo IgE-reactivity was investigated by the skin prick test.
Results: Both the recombinant and the mutated form of Sal k 1 were expressed in E. coli at a relatively high
amount and soluble form. All sera recognized rSal k 1 via immunoassay analysis. In addition, inhibition assays
demonstrated that the purified rSal k 1 was similar to its counterpart in the crude extract. The mutated rSal k 1
exhibited a reduced IgE-binding capacity against wild-type rSal k 1.
Conclusions: This study demonstrates that purified rSal k 1 is comprised of IgE-epitopes similar to that of its
natural counterpart and that the mutated variant showed a reduced IgE-binding capacity based on in vitro as-
says and in vivo provocation testing.
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INTRODUCTION
Salsola is one of the most well known genera in the
family of Chaenopodiacea. The members of this gen-
era, especially Salsola kali; also known as Russian
thistle, and Salsola incanescens produce high quanti-
ties of pollen grains and are abundant throughout the
desert and semi-desert regions of Iran.1-4 Moreover,
pollens from various genera of Chenopodiaceae are
the most common cause of pollinosis in the western
United States, Europe and Asia.5 In Iran and other
semi-arid countries such as Saudi Arabia and Kuwait,
inhalation of these pollens is one of the most typical
causes of allergic respiratory symptoms in which the
frequency of sensitization ranges from 53% to
76.7%.2,4,6,7
Recently, a S. kali pollen-allergen was identified.
Having an apparent molecular weight of 40 kDa, it
also displayed pectin methylesterase (PME) proper-
ties. This allergen was named Sal k 1 and is consid-
ered a major allergen of S. kali pollen, as determined
by Spanish salsola pollen-allergic patients.5,8 In addi-
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Table 1 Clinical characteristics, SPT responses and IgE-reactivity of the selected patients with alergy to S. kali polen
S. kali extractTotal IgE 
IU/mlClinical history 
†Age (years)/sexSample No. Specific IgE§Skin test ‡
Patients
1.10371700AR28/M 1.
0.89281320AR, RC22/F 2.
0.90311200AR23/F 3.
1.13332010AR30/M 4.
1.02361150AR, RC27/F 5.
0.80251980AR26/F 6.
1.08322010AR, RC36/F 7.
0.84301500AR27/M 8.
1.07411820AR26/M 9.
0.89221900AR32/F10.
Controls
0.10- 700AR34/F11.
0.10- 550AR23/M12.
0.08-  88-28/M13.
0.09-  70-35/F14.
† AR, alergic rhinitis; RC, rhiniconjectivits.
‡ The mean wheal areas are displayed in mm2. Histamine diphosphate (10 mg/ml) -positive control; Glycerin-negative control.
§ Determined in ELISA as OD (optical density) at 450 nm.
tion, more recently, we identified, characterized and
submitted two other new allergens from S. kali pollen
to the WHOIUIS Allergen Nomenclature Subcom-
mittee: Sal k 3, an approximately 85-kDa protein with
methionine synthase properties; and Sal k 4, a profilin
protein, (unpublished data). Due to the fact that suffi-
cient quantities of allergens are essential for the de-
velopment of in vitro and in vivo diagnosis of pollen-
allergic diseases, many allergenic molecules have
been cloned and expressed as recombinant proteins.
During the last decade, the production of recombi-
nant allergens has in turn allowed scientists to over-
come many limitations of cross-reactivity studies and
epitope complexities at the molecular level.9 More-
over, the availability of purified and well-defined re-
combinant forms of allergens and low IgE-binding or
hypoallergenic variants of common and critical aller-
gens has presented new opportunities both for devel-
oping diagnostic assays and therapeutic strategies
and for creating specific preventive products.
Natural Sal k 1 has been previously purified8 and
cloned5 as the major allergen of S. kali pollen. How-
ever, to our knowledge, it has not yet been ex-
pressed. For the first time, in this study, we produced
the soluble form of the recombinant and hypoaller-
genic variants of Sal k 1 in Escherichia coli. After puri-
fication, the allergenic reactivity of these proteins was
compared by employing the skin prick test and im-
munoblotting analysis with the sera from S. kali aller-
gic patients.
METHODS
PATIENT POPULATION AND SKIN PRICK TEST
(SPT)
Ten patients, six women and four men (mean age,
27.70 ± 4.13 years; age range, 22-36 years), present-
ing to the Immunology Research Center of Avicenna
Research Institute were included in our study on the
basis of a past medical history indicating a S. kali pol-
len allergy without asthma and a positive SPT to S.
kali pollen extract (Table 1).
Two grams of the Salsola kali defatted pollen with a
purity of more than 95% (purchased from Greer Labo-
ratories, USA) were extracted as described previ-
ously.4 The protein content of the extract was meas-
ured by the Bradford’s method.10 Skin prick tests
were performed with S. kali pollen extract and also
with purified wild-type and mutated recombinant Sal
k 1 (at concentrations of 5, 10, 15 and 20 μgml) on
the inner left forearms. After 15 minutes, the mean di-
ameter of the wheal reaction in every patient was
measured and compared with negative (50% Glyc-
erin) and positive (histamine diphosphate, 10 mgml)
controls. SPT with a wheal diameter >3 mm were con-
sidered positive compared to results obtained with
negative and positive controls. Informed written con-
sent was obtained from each patient and the study
protocol was approved by the Human Ethics Commit-
tee of the Avicenna Research Institute.
rSal k 1 and Its Mutated Variant
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Fig. 1 (A) Schematic representation of expression vector, pET-32b (+)/Sal k 1, with T7 promoter, a fusion part-
ner of thioredoxin (TrxA), two hexahistidyl (6 × His) afinity tag at the 5’ and 3’ ends of the Sal k 1 coding se-
quence and ampicilin resistance gene. (B) Schematic view of unprocessed natural Sal k 1 with putative signal 
peptide (upper), TrxA-rSal k 1 (middle) and TrxA-Mut-rSal k 1 (lower). The mutated amino acid residues are 
shown in bold.
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Fig. 2 Three-dimensional view of Sal k 1. (A) Ribbon style of Sal k 1 with the three amino acid residues core-
sponds to predicted B-cel epitope. The conformation of the amino acid residues are trans (R142, P143 and 
D144). (B) Space-filing model of Sal k 1 with predicted B-cel epitope (amino acids 135-150, are shown with 
closed line) and critical amino acids residues (Arg142, Pro143 and Asp144). (C) Mutated Sal k 1 (Mut-Sal k 1) 
with three point mutations (Arg142→Ser, Pro143→Ala and Asp144→Val).
(A) (B) (C)
AMPLIFICATION OF Sal k 1 cDNA BY RT-PCR
AND DETERMINATION OF NUCLEOTIDE SE-
QUENCE
Coding sequences of Sal k 1, without putative signal
sequence, were amplified using degenerate primers
designed according to reported nucleotide sequences
of Sal k 1 (AY776248, AY776249, AY590141): sense
primer, 5´-CAAGCCTAGATCTCCACCCACT
AATCC-3´; and anti-sense primer, 5´-CACCTTTA
CTGGCTGGCTGGATAGGTAGCCA-3´. A PCR
product of 1017 bp length was cloned into the
pTZ57RT vector (Fermentas, Vilnius, Lithuania) and
transformed into a non-expression host, E. coli cells
strain TOP10 (Invitrogen, San Diego, CA, USA). The
isolated plasmids (pTZ57RT-Sal k 1) were se-
quenced by the dideoxy method and analyzed by an
automatic sequencer (SeqLab, Göttingen, Germany).
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CONSTRUCTION OF PROKARYOTIC EXPRES-
SION PLASMID CARRYING THE Sal k 1 GENE
The obtained nucleotide sequence allowed for the de-
signing of these two non-degenerate primers accord-
ing to the 5´ and 3´ ends of the Sal k 1 cDNA: the
sense primer, 5´-TCCGCGGCCGCACAGCTGATTCC
CCCTAATCC-3´ (with the Not I site underlined); and
the anti-sense primer, 5´-TCTCTCGAGCACTTTCGG
TGGTGGAGGTA-3´ (with the Xho I site underlined).
The amplified product was digested with Not I and
Xho I (both from Fermentas, Vilnius, Lithuania) and
ligated into the pET-32b(+) expression vector (No-
vagen, Gibbstown, NJ, USA) that was restricted with
the same enzymes. The resulting expression con-
struct, pET-32b(+)Sal k 1 (Fig. 1), was transformed
into competent BL21 (DE3) E. coli cells (Novagen,
Gibbstown, NJ, USA) and the obtained positive
clones were confirmed by restriction digestion analy-
sis and sequencing.
MODELING, B-cell EPITOPE PREDICTION AND
SITE-DIRECTED MUTAGENESIS OF Sal k 1
Homology model of Sal k 1 was generated using the
coordinates from the pectin methylesterase of Er-
winia chrysanthemi (PDB number: 1QJV) by the In-
ternet server Swiss Model (http:swissmodel.
expasy.orgSWISS-MODEL.html), as previously re-
ported (Fig. 2A).
We used ABCpred, B cell epitope prediction soft-
ware based on trained recurrent neural network
(RNN), and Bcepred, a method for prediction of con-
tinuous B-cell epitopes in antigenic sequences using
physico-chemical properties, for prediction of IgE-
binding epitopes.11,12
We generated the Sal k 1 mutant (R142→S, P143→A,
D144→V) by using the PhusionTM Site-Directed
Mutagenesis Kit (FINNZYMES, Espoo, Finland) ac-
cording to the manufacturer’s instructions and by em-
ploying the mutagenic oligonucleotide (5´-CTCCAAG
cgCAGtTGGAAAAA-3´, with the mutant nucleotides
indicated in lowercase). The expression construct
pET-32b(+)Sal k 1 was used as a template. The se-
quences of the mutated clones were confirmed by se-
quencing.
EXPRESSION AND PURIFICATION OF WILD-
TYPE AND MUTATED rSal k 1 (Mut-rSal k 1)
The E. coli expression strain BL21 (DE3)pLysS (Invi-
trogen, San Diego, CA, USA) was transformed by re-
combinant plasmids harboring the wild-type or Mut-
rSal k 1 genes. It was cultured in LB medium contain-
ing 50 μgmL of ampicillin and incubated at 37℃.
Subsequent to reaching an OD600 of 0.4, protein ex-
pression was induced by the addition of isopropyl-β-
D-thiogalactosidase (IPTG) to a final concentration of
0.2 mM. Following induction, in order to improve the
solubility of recombinant proteins, the cultures were
incubated at 18℃ and cells were grown for 12 hours,
after induction. The cells were then disrupted by
freezing in liquid nitrogen followed by thawing at
37℃. This freeze-thaw cycle was repeated three
times. Insoluble materials were removed from the
cell lysate by centrifugation at 12000 g for 20 minutes
at 4℃. The supernatant containing expressed rSal k 1
or Mut-rSal k 1 was transferred to new tubes and
stored at -20℃ until use.
The purification of rSal k 1 and Mut-rSal k 1 was
performed according to the IMAC (Immobilized
Metal Affinity Chromatography) column using Ni-
NTA agarose (Invitrogen) and by following the manu-
facturer’s instructions. Protein concentration was de-
termined according to the Bradford’s method.10
TOTAL AND DIRECT ELISA
Total serum levels of IgE were measured in duplicate
by a commercial ELISA kit (RADIM, Pomezia, Italy)
according to the manufacturer’s instructions. To de-
termine the specific IgE reactivity of S. kali pollen ex-
tract, all ten sera were evaluated by ELISA. The four
subjects who showed negative SPT responses to S.
kali pollen extract (Table 1, sample numbers 11-14)
were also used as negative controls. Ninety-six-well
ELISA microplates (Nunc Maxisorb, Roskilde, Den-
mark) were coated with S. kali pollen extract (10 μg
well in 0.1 M sodium bicarbonate, pH 9.6), rSal k 1 or
Mut-rSal k 1 (5 μgwell in 0.1 M sodium bicarbonate,
pH 9.6) and incubated overnight at 4℃. Plates were
then washed four times with PBS (pH 7.4, containing
0.05% Tween-20) and blocked with PBS1% bovine se-
rum albumin (BSA) for one hour at 37℃. After wash-
ing, 100 μl of the diluted patients’ sera (1 : 2 in PBS
0.05 Tween-200.3% BSA) were added to each well
and the plates were incubated overnight at room tem-
perature. Plates were washed again and then incu-
bated with biotinylated anti-human IgE (KPL, MD,
USA) (1 : 1000 vv in 1% BSA) for two hours at room
temperature. The unbound antibodies were removed
from the wells by washing, which was followed by in-
cubation with 1 : 40000 vv in BSA1% HRP-linked
streptavidin (BD Biosciences, MD, USA) for 45 min-
utes at room temperature. After visualization of the
enzymatic activity with tetramethylbenzidine (TMB)
as a substrate at 37℃ for 15 minutes, the reaction was
stopped by the addition of 100 μl of 3N HCl, and ab-
sorption was measured at 450 nm. Optical density
(OD450) greater than four times the median values of
negative controls were considered as positive.
ELISA INHIBITION
ELISA inhibition assays were performed as above,
with the exception of a pooled serum (1 : 2 vv) from
S. kali allergic patients (Nos. 1, 2, 4, 6, 7, 9 and 10)
which were preincubated for one hour at room tem-
perature with 0.01, 0.1, 1, 10 and 100 μg of each in-
hibitor or with BSA as a negative control. Assays
were performed in duplicate. The percentage of inhi-
rSal k 1 and Its Mutated Variant
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Fig. 3 The comparison of Sal k 1 amino acid sequence (ACO34813) (without signal peptide) with three diferent iso-
forms previously deposited in database banks (AAX11262, AAX11261, AAT99258) and pectin methylesterases from 
Daucus carota (carot) (P83218) and Erwinia chrysanthemi (a gram-negative bacilus) (P07863). The ful-length of Sal k 
1 consists of 362 amino acids including a putative signal peptide of 23residues. The cleavage position of signal peptide is 
between Ala23 and Gln24. The catalytic residues Gln151, Gln173, Asp174, Asp195 and Arg253 are shaded in gray. 
Numbers at right side showed the length of each sequence. Percentage of sequence identity and similarity with respect 
to Sal k 1 (ACO34813) are included at the botom right of the figure.
bition was calculated using the following formula:
(OD of sample without inhibitor - OD of sample with
inhibitorOD of sample without inhibitor) × 100.
IgE-IMMUNOBLOTTING AND IMMUNOBLOT-
TING INHIBITION
The S. kali pollen extract was fractionated by the
means of SDS-PAGE in accordance with the Laemmli
method13 on Bio-Rad Miniprotean II System gels
(12.5% polyacrylamide) and then electrotransferred
onto polyvinylidene difluoride (PVDF) membranes,
as previously explained.4 Moreover, 5 μgcm gel of
purified rSal k 1 or mutated rSal k 1 (Mut-rSal k 1)
was separated by the SDS-PAGE, and PVDF strips
containing equal amount of blotted rSal k 1 or Mut-
rSal k 1 was then exposed to sera from the patients.
The IgE-immunoblot inhibition experiment was
performed as described previously,4 except that the
pooled sera (1 : 5 vv) from S. kali allergic patients
were preincubated for 3 hours at room temperature
with equal volumes of purified inhibitors or with PBS-
BSA as negative control.
RESULTS
PCR AMPLIFICATION AND CLONING OF Sal k 1
cDNA AND SEQUENCING OF PCR PRODUCTS
Total RNA was obtained from S. kali pollen, followed
by the synthesis of the first cDNA strand and PCR us-
ing a pair of degenerate primers designed accord-
ing to the reported nucleotide sequences of Sal k 1
(AY776248, AY776249, AY590141).5 The size of the
PCR product was approximately 1017 bp. The nucleo-
tide sequence of Sal k 1 was deposited in GenBank
NCBI databases under the accession number of
FJ821453. The sequence analysis of the mature (proc-
essed) form of Sal k 1 showed an open-reading frame
of 1017 bp length coding for 339 amino acid residues
with a predicted molecular mass of 36.793 kDa, a cal-
Assarehzadegan MA et al.
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Fig. 4 (A) Reducing SDS-PAGE of S. kali polen crude extract, TrxA-rSal k 1 and TrxA-Mut-rSal k 1 on 
12.5% acrylamide gel (Coomassie staining). Lane M: low molecular weight (Amersham, Buckingham-
shire, UK); Lane 1: Purified TrxA-rSal k 1; Lane 2: Purified TrxA-Mut-Sal k 1; (B) IgE-Immunoblot of  S. 
kali polen extract using alergic patients’ sera; lane M, Low molecular weight (Amersham); lanes 1-10: 
Probed with individual alergic patients’ sera; lane C-: negative control; (C) IgE-immunobloting analysis of 
rSal k 1 using 10 alergic patients. Lane M: low molecular weight (Amersham); lane 1-10: bloted rSal k 1 
probed with individual S. kali -alergic patients’ sera; lane C-: negative control. (D) IgE-immunobloting 
analysis of wild-type and mutated rSal k 1; equal amounts of purified rSal k 1 and Mut-rSal k 1 were sub-
jected to SDS-PAGE, bloted onto a PVDF membrane and probed with two pooled sera consisting of S. 
kali alergic patients 1-5 (pooled serum 1) and patients 6-10 (pooled serum 2).
culated pI of 7.7, and a potential N-glycosylation site
at Asn-267. According to an earlier study,5 the un-
processed protein consists of 362 amino acids includ-
ing a putative signal peptide of 23 residues. More-
over, the suggested cleavage position for processing
of mature Sal k 1 is located between Ala23 and Gln
24.5
The amino acid sequence comparisons of the de-
posited Sal k 1 (ACO34813) (without signal peptide of
23 amino acids) with those of previously reported iso-
forms of Sal k 1 (AAX11262, AAX11261, AAT99258),
and with pectin methylesterases from Daucus carota
(carrot) (P83218) and a gram-negative bacillus, Er-
winia chrysanthemi (P07863), are showed in Figure 3.
EXPRESSION AND IMMUNOREACTIVITY OF
NATURAL AND RECOMBINANT Sal k 1
The pET-32b(+)Sal k 1 clone was successfully con-
structed and confirmed by digestion with Not I and
Xho I restriction enzymes and sequencing. This re-
combinant plasmid containing TrxA, to increase the
solubility, and his-tags, for Ni-NTA purification, was
expressed in E. coli strain BL21 (DE3)pLysS as an ap-
proximately 56-kDa recombinant protein (TrxA-rSal k
1). According to the Bradford’s method,10 concentra-
tion of the purified recombinant protein (rSal k 1) and
the Mutated rSal k 1 (Mut-rSal k 1) were approxi-
mately 1.1 and 1.3 grams per 1 liter of expression me-
dium, respectively (Fig. 4A).
Immunoblot analysis revealed that all selected pa-
tients were reactive to natural Sal k 1 pollen (Fig. 4
B). Moreover, all ten S. kali allergic patients’ sera re-
acted to recombinant Sal k 1, in contrast to the
healthy control sera which exhibited no reaction (Fig.
4C).
IgE-binding reactivity of the purified TrxA protein
was evaluated by immunoblotting and ELISA assays
and showed no reaction with the pooled sera from S.
kali allergic patients (data not shown).
Inhibition experiments were performed to investi-
gate the IgE-binding potential of the purified rSal k 1
in comparison with its natural counterpart. The re-
sults showed that pre-incubation of serum samples
with the native crude extract of S. kali pollen (Fig. 5,
lane 2) or rSal k1 (Fig. 5, lane 3) completely inhibited
IgE binding to natural Sal k1. However, preincubation
of the pooled serum with PBS-BSA (Fig. 5, lane 1) or
the purified TrxA protein (data not shown) did not af-
fect IgE binding. These results demonstrated that the
recombinant protein allergen (rSal k 1) had a high
degree of immunological identity with its natural
counterpart.
Moreover, the specific IgE values from the S. kali
pollen extract (Table 1) and purified rSal k 1 were de-
termined using ten individual patients’ sera. (Table
2). All patients exhibited significantly elevated spe-
cific IgE when tested with the S. kali pollen extract or
with the purified rSal k 1.
Mut-rSal k 1 SHOWS REDUCED IgE-BINDING
REACTIVITY
The results of B-Cell epitope prediction using
rSal k 1 and Its Mutated Variant
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Table 2 Skin prick tests and specific ELISA with rSal k 1 and Mut-rSal k 1
Specific IgE ‡Skin prick test †
Patients TrxA-Mut-
rSal k 1
TrxA-rSal 
k 1GlycerinHistamine
TrxA-Mut-rSal k 1 (μg/ml)TrxA-rSal k 1 (μg/ml)
20151052015105
0.520.90015151083302015 5 1.
0.410.7901310 800251510 5 2.
0.450.8501413 8422815 6 4 3.
0.490.9502020159431251810 4.
0.510.9201818129532201210 5.
0.380.7501212 5001912 5 3 6.
0.400.88012151262282512 5 7.
0.400.80015171281252015 4 8.
0.580.9601623159640252012 9.
0.360.7801010 400181310 410.
0.450.85014.515.310.15.32.327.619.012.36.2Mean
(0.71)(0.75)(0)(2.9)(4.2)(3.8)(3.9)(2.1)(6.4)(5.0)(4.8)(3.1) (±SD)
† The mean wheal areas are displayed in mm2. Histamine diphosphate (10 mg/ml) -positive control; Glycerin-negative control. The 
wheals induced by Mut-rSal k 1 were significantly smaler than the ones obtained with rSal k 1 (p < 0.001) using student’ st test.
‡ Determined in ELISA as OD (optical density) at 450 nm. The OD values of Mut-rSal k 1 is statisticaly lower than the ones with rSal 
k 1 (p < 0.001) .
kDa
1M 2 3
97.0
66.0
45.0
Sal k 1
30.0
20.1
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Fig. 5 IgE-immunobloting inhibition analysis. The polen 
extract of S. kali was separated by SDS-PAGE and bloted 
onto PVDF. IgE-binding of a pooled serum, including that of 
four S. kali polen alergic patients, Nos. 1, 3, 4 and 8, were 
studied after preincubation with PBS-BSA (lane 1), S. kali 
extract (50 μg/ml) (lane 2) and purified rSal k 1 (50 μg/ml) 
(lane 3). Lane M, low molecular weight (Amersham).
ABCpred, a predictive software based on artificial re-
current neural network (RNN), indicated that the
peptide corresponding to amino acids 135-150 was
one of the most dominant B-cell epitopes of Sal k 1
(Fig. 2B, C). Three other dominant B-cell epitopes
were the peptides corresponding to amino acids 52-
67, 274-289 and 214-229.
Mut-r Sal k 1 was expressed in E. coli strain BL21
(DE3)pLysS and purified by Ni-NTA agarose accord-
ing to procedures described earlier for wild-type rSal
k 1.
The evaluation of the IgE-binding reactivity of Mut-
rSal k 1 with three amino acid substitution compared
to that of wild-type rSal k 1 was performed by im-
munoblot assays using two pooled sera from ten aller-
gic patients. Figure 4D shows the IgE-binding reac-
tivity of two pooled sera from allergic patients to wild-
type and Mut-rSal k 1. Both of the two pooled sera
displayed low IgE-binding reactivity to Mut-rSal k 1
compared to the wild-type rSal k 1. Therefore, it ap-
peared that the amino acid substitutions were effec-
tive in reducing the IgE-binding capacity of Sal k 1.
The direct ELISA assay with Mut-rSal k 1 indicated
that the IgE-binding capacity of this mutated recombi-
nant protein was significantly lower than that of wild-
type rSal k 1 (p < 0.001) (Table 2). Also, using a
pooled serum from the allergic patients, ELISA inhi-
bition assays were performed to evaluate the inhibi-
tion of IgE-binding to immobilized wild-type rSal k 1
by its mutated counterpart. The results showed that
the Mut-rSal k 1 exhibited a much lower inhibition ca-
pacity than the wild-type recombinant protein (Fig.
6).
Assarehzadegan MA et al.
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Fig. 6 Inhibition of IgE-binding to rSal k 1 by ELISA using S. kali polen extract, rSal k 1, 
and -Mut-rSal k 1. Control experiments were performed with BSA.
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Fig. 7 Ability of purified rSal k 1 and Mut-rSal k 1 to elicit 
immediate skin reactions. The results of skin prick test on a 
S. kali alergic patient (patient No. 9) with diferent concentra-
tions (5, 10, 15 and 20 μg/ml) of rSal k 1 and Mut-rSal k 1 
are presented. Histamine diphosphate (10 mg/ml) (Histami-
ne) and glycerin were used as positive and negative control, 
respectively. The wheal reactions were marked with a bal-
point pen.
Mut-rSal k 1 HAS A REDUCED ABILITY TO
ELICIT IMMEDIATE CUTANEOUS REACTIONS
The capacity of the wild-type Sal k 1 and Mut-rSal k 1
to induce immediate skin reactions were investigated
in ten S. kali allergic patients by in vivo SPTs (Table
2). All of the allergic patients showed a positive cuta-
neous reaction to wild-type rSal k1 at different con-
centrations (5, 10, 15 and 20 μgml). Following the
application of Mut-rSal k 1 on the inner left forearm of
allergic patients, three patients (Nos. 2, 6 and 10)
showed negative SPT at concentrations of 5 and 10
μgml. The mean wheal areas induced by different
concentrations of Mut-rSal k 1 were significantly
smaller than those obtained with rSal k 1 (p < 0.001)
(Table 2, Fig. 7). In control patients, no skin reactions
were elicited with the application of purified rSal k 1
or Mut-rSal k 1.
DISCUSSION
Sal k 1 is an allergenic member of the pectin meth-
ylesterase superfamily. Several allergens from this
superfamily, such as Bet v 8 and a 34-kDa-protein of
tomato,14,15 have already been identified. In this
study, we produced wild-type rSal k1 as a major aller-
gen of S. kali pollen, along with a low IgE-binding
variant of rSal k 1 (Mut-rSal k 1), both in E. coli. In
addition, it was demonstrated that generating a low
IgE-binding rSal k 1 variant by the exchange of amino
acid residues via a site-directed mutagenesis is possi-
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ble.
Baraderas et al. showed that the purified natural
Sal k 1 like the one in the total extract reacted to all
eleven allergic patients’ sera.5 Concurrently, in the
present study, natural Sal k 1 in total extract of S. kali
pollen was recognized by all of the patients’ sera.
This study evaluated the IgE-binding ability of puri-
fied rSal k 1 to the sera from ten S. kali allergic pa-
tients by immunoblotting assays in order to confirm
that the recombinant protein was equivalent to its
natural counterpart and correctly folded. The results
revealed that, similar to natural Sal k 1 in total extract
of S. kali pollen, all sera reacted with rSal k 1.
In addition, complete inhibition of IgE-binding to
natural Sal k 1 was obtained after preincubation of
pooled serum with purified recombinant Sal k 1.
Moreover, the results of the ELISA inhibition experi-
ments were entirely consistent with those obtained
from immunoblotting assays. Regarding these re-
sults, it appears that rSal k 1 is comprised of IgE-
epitopes, similar to that of its natural counterpart.
Among four defined allergens from S. kali pollen
(Sal k 1, Sal k 2, Sal k 3 and Sal k 4, submitted to
WHOIUIS), the study selected Sal k 1 to generate a
low IgE-binding variant. This was for two reasons.
First, Sal k 1 is the most abundant protein in S. kali
pollen extract.8 Second, the results, in accordance
with previous studies, showed that almost 100% of S.
kali pollen allergic patients reacted to Sal k 1.5,8 How-
ever, several studies indicated that in addition to Sal k
1, there are a number of other allergenic components
in the total extract of S. kali pollen, which are fre-
quently recognized by specific IgE.1,4,5,8,16
SDS-PAGE results showed that the pattern of mi-
gration of the Sal k 1 was not changed under both
non-reducing and reducing conditions (data not
shown). This was in accordance with the previous
study8 and suggests that five cysteine residues of Sal
k 1 may be associated with intrachain disulfide
bonds.
Several studies have demonstrated that it is possi-
ble that a few changes in critical residues from the
predicted epitope region for antibody binding drasti-
cally decrease the IgE-binding capacity of the epi-
tope.17-21 Accordingly, the strategy to generate rSal k
1 with a low IgE-binding capacity (Mut-rSal k 1) was
based on the exchange of the three amino acid resi-
dues (Arg142→Ser, Pro143→Ala, Asp144→Val) of the
dominant predicted B cell epitope located around the
middle sequence of this recombinant protein. It is
noteworthy that, based on Bcepred, a continuous B-
cell epitope prediction software,12 all three residues
are among the most accessible, flexible and hydro-
philic residues in Sal k 1; in addition, the residue Asp
144 has the highest antigenic propensity.
Using the B cell epitope prediction software, all the
possible exchanges of one or more amino acid resi-
dues were evaluated to select the most appropriate
amino acid substitutions to reduce the antigenic pro-
pensity of the peptide corresponding to amino acids
135-150. Nevertheless, further epitope mapping ex-
periments are necessary to demonstrate the effect of
exchange of each residue on decreasing the IgE-
binding capacity of the predicted B cell epitope.
Moreover, Takai et al. showed that replacement of
proline with alanine may be an efficient strategy for
reducing of IgE-binding activity of Der f 2.22
Based on the previous studies, it is possible to re-
duce the IgE-binding activity of an allergen by a few
point mutations without considerably alteration of the
overall structural fold of the molecule.23,24 Moreover,
analysis of Sal k 1 and Mut-Sal k 1 molecular models
by PROCHECK25 and evaluation of predicted confor-
mational B cell epitopes with CEP (http:bioinfo.
ernet.incep.htm) and SEPPA (http:lifecenter.sgst.
cnseppasubmit.php) software seem not to signifi-
cantly alter the similarity exhibited between the two
models.
To exchange critical residues and modify one of
dominant predicted B cell epitopes of rSal k 1, in vitro
site-directed mutagenesis was used. This method has
been effectively performed in several studies for de-
creasing or abolishing the IgE-binding capacity of al-
lergenic recombinant proteins.18,19,24,26
The findings of the study are in line with several
previous studies which demonstrated that manipu-
lated allergen variants are shown to elicit a reduced
IgE reactivity.23,24,26
The IgE-binding reactivity of allergenic proteins is
usually assessed by SPT.17,27,28 Thus, this study em-
ployed SPT to compare the ability of wild-type rSal k
1 with its mutated variant (Mut-rSal k 1) to elicit IgE-
mediated reactions. Indeed, SPT was used to imitate
early cutaneous allergic reactions (characterized by a
local edema known as wheal). The results showed a
reduction in the IgE-binding reactivity of Mut-rSal k 1
compared to that of wild-type rSal k 1. However, the
findings of SPTs revealed variations among allergic
patients in immediate cutaneous reactions to both
wild-type and mutated rSal k 1. This is in accordance
with previous studies.18,29
Taken together, the results of in vitro and in vivo
assays indicate that amino acid positions 142, 143 and
144 may play an important in the IgE-binding reactiv-
ity of the Sal k 1 allergen.
In conclusion, this study demonstrates that purified
rSal k 1 is comprised of IgE-epitopes similar to that of
its natural counterpart and that the mutated variant
(Mut-rSal k 1) showed a reduced IgE-binding capac-
ity based on in vitro assays and in vivo provocation
testing. All together, these recombinant proteins
could be effective candidates for further studies on
cross-reactivity and the development of diagnostic
and therapeutics approaches.
Assarehzadegan MA et al.
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